The US Food and Drug Administration has officially granted approval to Teva Pharmaceuticals for Weltruza, a brand-new once-monthly subcutaneous long-acting injection designed specifically for adults battling schizophrenia. Developed in partnership with Medincell, this extended-release formulation of olanzapine marks a massive step forward in patient adherence and healthcare logistics. Clinical trials demonstrated that Weltruza significantly reduces overall illness severity, stabilizes volatile symptoms, and substantially elevates the day-to-day personal and social functioning of patients compared to traditional oral regimens.
About the Author
